RT Journal Article
SR Electronic
T1 The effect of a national lockdown in response to COVID-19 pandemic on the prevalence of clinical symptoms in the population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20076000
DO 10.1101/2020.04.27.20076000
A1 Keshet, Ayya
A1 Gavrieli, Amir
A1 Rossman, Hagai
A1 Shilo, Smadar
A1 Meir, Tomer
A1 Karady, Tal
A1 Lavon, Amit
A1 Kolobkov, Dmitry
A1 Kalka, Iris
A1 Shoer, Saar
A1 Godneva, Anastasia
A1 Cohen, Ori
A1 Zohar, Anat Aka
A1 Irony, Angela
A1 Geiger, Benjamin
A1 Dor, Yuval
A1 Balicer, Ran
A1 Shalev, Varda
A1 Segal, Eran
YR 2020
UL http://medrxiv.org/content/early/2020/05/01/2020.04.27.20076000.abstract
AB ‘SARS-CoV-2’, a novel coronavirus and the cause of COVID-19, was isolated in December 2019 and has since been declared a pandemic by the World Health Organization (WHO). The vast and rapid spread of COVID-19 calls for immediate action from policy-makers and in many countries, various lockdown measures were implemented. Here, we utilized nationwide surveys that assess COVID-19 associated symptoms to analyse the effect of the lockdown policy in Israel on the prevalence of clinical symptoms in the population. Daily symptom surveys were distributed online and included fever, respiratory symptoms, gastrointestinal symptoms, anosmia and Ageusia. A total of 1,003,298 surveys were filled up to date. We used a single measure of symptoms, Symptoms Ratio (SR), defined as a weighted mean of symptoms found to be prevalent in COVID-19 patients. Notably, following severe lockdown measures, we found that between March 15th and April 22nd, the mean SR sharply declined by 78.9%, as did every individual symptom, including our most common symptoms of cough and rhinorrhea or nasal congestion, which decreased from 14.5% and 13.8% of the survey responders, respectively, to 2.4% and 2.5%. We also observed reduction in symptoms separately in the vast majority of cities in Israel. Overall, these results demonstrate a profound decrease in a variety of clinical symptoms following the implementation of a lockdown in Israel. As our survey symptoms are not specific to COVID-19 infection, this effect likely represents an overall nationwide reduction in the prevalence of infectious diseases, including COVID-19. This quantification may be of major interest for COVID-19 pandemic, as many countries consider implementation of lockdown strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTables of de-identified, aggregated data are available at https://github.com/hrossman/Covid19-Survey. https://github.com/hrossman/Covid19-Survey